Antiresorptive therapies for osteoporosis: a clinical overview (Q37926914)

25 August 2017

1 reference

title

Antiresorptive therapies for osteoporosis: a clinical overview (English)

1 reference

25 August 2017

0 references

Jian Sheng Chen

1

1 reference

PubMed ID

21894214

25 August 2017

Philip N Sambrook

series ordinal

2

1 reference

25 August 2017

6 September 2011

1 reference

Nature Reviews Endocrinology

25 August 2017

1 reference

25 August 2017

8

1 reference

25 August 2017

2

1 reference

25 August 2017

81-91

1 reference

https://scigraph.springernature.com/pub.10.1038/nrendo.2011.146

25 August 2017

0 references

cites work

How many women have osteoporosis now?

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Osteoporosis is markedly underdiagnosed: a nationwide study from Denmark

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

An estimate of the worldwide prevalence and disability associated with osteoporotic fractures

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Low-trauma fractures indicate increased risk of hip fracture in frail older people.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Management of osteoporosis in primary care in Australia

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Secondary osteoporosis in patients with an osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Endogenous estrogen levels and the effects of ultra-low-dose transdermal estradiol therapy on bone turnover and BMD in postmenopausal women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Clinical practice. Postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of raloxifene on fracture risk in postmenopausal women: the Raloxifene Use for the Heart Trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Alendronate for the Treatment of Osteoporosis in Men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Alendronate treatment of established primary osteoporosis in men: results of a 2-year prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risedronate sodium therapy for prevention of hip fracture in men 65 years or older after stroke

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Comparative effects of teriparatide and strontium ranelate on bone biopsies and biochemical markers of bone turnover in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Skeletal effects of raloxifene after 8 years: results from the continuing outcomes relevant to Evista (CORE) study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Improvement in spine bone density and reduction in risk of vertebral fractures during treatment with antiresorptive drugs

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Prevention of osteoporosis-related fractures among postmenopausal women and older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Ibandronate for the prevention of nonvertebral fractures: a pooled analysis of individual patient data

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Clodronate reduces vertebral fracture risk in women with postmenopausal or secondary osteoporosis: results of a double-blind, placebo-controlled 3-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Oral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bisphosphonate use and the risk of adverse jaw outcomes: a medical claims study of 714,217 people

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bisphosphonate use in women and the risk of atrial fibrillation: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Severely suppressed bone turnover: a potential complication of alendronate therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Subtrochanteric and diaphyseal femur fractures in patients treated with alendronate: a register-based national cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Exposure to oral bisphosphonates and risk of esophageal cancer.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Zoledronic acid and clinical fractures and mortality after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Potential mediators of the mortality reduction with zoledronic acid after hip fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Osteoporosis medication and reduced mortality risk in elderly women and men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effect of osteoporosis treatment on mortality: a meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Hormone replacement therapy and prevention of vertebral fractures: a meta-analysis of randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bone response to treatment with lower doses of conjugated estrogens with and without medroxyprogesterone acetate in early postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Meta-analyses of therapies for postmenopausal osteoporosis. IV. Meta-analysis of raloxifene for the prevention and treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Lasofoxifene in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

New selective estrogen receptor modulators (SERMs) in development

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Salmon calcitonin: a review of current and future therapeutic indications

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

The analgesic role of calcitonin following osteoporotic fracture

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Meta-analyses of therapies for postmenopausal osteoporosis. VI. Meta-analysis of calcitonin for the treatment of postmenopausal osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effect of denosumab on bone density and turnover in postmenopausal women with low bone mass after long-term continued, discontinued, and restarting of therapy: a randomized blinded phase 2 clinical trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Denosumab for prevention of fractures in postmenopausal women with osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Mortality after all major types of osteoporotic fracture in men and women: an observational study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Mortality, morbidity, and assessment of fracture risk in male osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Pathogenesis of vertebral crush fractures in men

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Alendronate treatment of established primary osteoporosis in men: 3-year results of a prospective, comparative, two-arm study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Efficacy of risedronate in men with primary and secondary osteoporosis: results of a 1-year study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Denosumab in men receiving androgen-deprivation therapy for prostate cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Once-weekly risedronate in men with osteoporosis: results of a 2-year, placebo-controlled, double-blind, multicenter study

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

The epidemiology of corticosteroid-induced osteoporosis: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

A revised clinician's guide to the prevention and treatment of osteoporosis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

FRAX and the assessment of fracture probability in men and women from the UK

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Estrogen and progestogen use in postmenopausal women: July 2008 position statement of The North American Menopause Society

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Relationship between pretreatment bone resorption and vertebral fracture incidence in postmenopausal osteoporotic women treated with risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Ten years' experience with alendronate for osteoporosis in postmenopausal women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Efficacy of continued alendronate for fractures in women with and without prevalent vertebral fracture: the FLEX trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

A systematic review of persistence and compliance with bisphosphonates for osteoporosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Factors affecting long-term compliance of osteoporotic patients with bisphosphonate treatment and QOL assessment in actual practice: alendronate and risedronate.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Determinants of adherence to osteoporosis treatment in clinical practice

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Adherence and persistence associated with the pharmacologic treatment of osteoporosis in a managed care setting.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Two-year effects of alendronate on bone mineral density and vertebral fracture in patients receiving glucocorticoids: a randomized, double-blind, placebo-controlled extension trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Five year study of etidronate and/or calcium as prevention and treatment for osteoporosis and fractures in patients with asthma receiving long term oral and/or inhaled glucocorticoids

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Zoledronic acid and risedronate in the prevention and treatment of glucocorticoid-induced osteoporosis (HORIZON): a multicentre, double-blind, double-dummy, randomised controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Vertebral Fracture Risk With Long-term Corticosteroid Therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of denosumab on bone mineral density and bone turnover in patients with rheumatoid arthritis receiving concurrent glucocorticoids or bisphosphonates

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bisphosphonate-Associated Osteonecrosis of the Jaw: Report of a Task Force of the American Society for Bone and Mineral Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risk of Subsequent Fracture After Low-Trauma Fracture in Men and Women

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Fracture risk following an osteoporotic fracture

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Transmission of human herpesvirus 8 by blood transfusion

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Etidronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risedronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Opinions and Experiences in General Practice on Osteoporosis Prevention, Diagnosis and Management

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Clodronate reduces the incidence of fractures in community-dwelling elderly women unselected for osteoporosis: results of a double-blind, placebo-controlled randomized study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Bisphosphonate-associated adverse events.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Oral bisphosphonates are associated with reduced mortality in frail older people: a prospective five-year study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Efficacy of raloxifene on vertebral fracture risk reduction in postmenopausal women with osteoporosis: four-year results from a randomized clinical trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effect of raloxifene therapy on venous thromboembolism in postmenopausal women. A meta-analysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risedronate and ergocalciferol prevent hip fracture in elderly men with Parkinson disease [RETRACTED]

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

The effect of intranasal salmon calcitonin therapy on bone mineral density in idiopathic male osteoporosis without vertebral fractures--an open label study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

High prevalence of asymptomatic vertebral fractures in post-menopausal women receiving chronic glucocorticoid therapy: a cross-sectional outpatient study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Calcitonin for the treatment and prevention of corticosteroid-induced osteoporosis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Adherence to treatment of primary osteoporosis and its association to fractures--the Swedish Adherence Register Analysis (SARA).

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Alendronate for the prevention and treatment of glucocorticoid-induced osteoporosis. Glucocorticoid-Induced Osteoporosis Intervention Study Group

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Risedronate therapy prevents corticosteroid-induced bone loss: a twelve-month, multicenter, randomized, double-blind, placebo-controlled, parallel-group study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effects of risedronate treatment on bone density and vertebral fracture in patients on corticosteroid therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRENDO.2011.146

Effect of intermittent cyclical etidronate therapy on corticosteroid induced osteoporosis in Japanese patients with connective tissue disease: 3 year followup.

31 March 2020

1 reference

12 December 2020

Hip fracture causes excess mortality owing to cardiovascular and infectious disease in institutionalized older people: a prospective 5-year study

1 reference

12 December 2020

Intermittent etidronate therapy to prevent corticosteroid-induced osteoporosis

1 reference

12 December 2020

How are family physicians managing osteoporosis? Qualitative study of their experiences and educational needs

1 reference

12 December 2020

A metaanalysis on the use of bisphosphonates in corticosteroid induced osteoporosis

1 reference

12 December 2020

Effects of testosterone replacement in hypogonadal men.

1 reference

12 December 2020

Identifiers

DOI

10.1038/NRENDO.2011.146

1 reference

25 August 2017

1 reference

PubMed ID

21894214